JOINN(603127)2022-03-30 16:00Financial Performance - The company's operating revenue for 2021 was approximately ¥1.52 billion, representing a 40.97% increase compared to ¥1.08 billion in 2020[17]. - The net profit attributable to shareholders for 2021 was approximately ¥557.46 million, a 76.96% increase from ¥315.01 million in 2020[17]. - The cash flow generated from operating activities in 2021 was approximately ¥685.66 million, up 60.06% from ¥428.39 million in 2020[17]. - The total assets at the end of 2021 were approximately ¥8.54 billion, a 305.02% increase from ¥2.11 billion at the end of 2020[17]. - The net assets attributable to shareholders at the end of 2021 were approximately ¥7.14 billion, reflecting a 482.60% increase from ¥1.22 billion at the end of 2020[17]. - The basic earnings per share for 2021 were ¥1.51, a 51.00% increase compared to ¥1.00 in 2020[18]. - The diluted earnings per share for 2021 were ¥1.50, representing a 51.52% increase from ¥0.99 in 2020[18]. - The weighted average return on equity for 2021 was 9.42%, down 21.36% from 30.78% in 2020[18]. - The company achieved a revenue of CNY 1,516.68 million in 2021, representing a year-on-year growth of 40.97%[64]. - The net profit attributable to shareholders was CNY 557.82 million, reflecting a year-on-year increase of 77.08%[64]. Investments and Capital Structure - The company plans to distribute a cash dividend of 3.6 CNY per 10 shares (including tax) and to increase capital by converting 4 shares for every 10 shares held[3]. - The company made strategic investments in Changchun Baike Biotechnology Co., Ltd. and Beijing Zhaoyan Biotechnology Co., Ltd., with total investments of ¥4,362 million and ¥5,000 million respectively, enhancing business cooperation and market competitiveness[78]. - The fair value of financial products increased to ¥605,533,634.18, up from ¥238,902,999.99 in the previous period, reflecting a strong growth in investment performance[80]. - The company reported a total of 1,135,000,000 RMB in entrusted financial management, with an outstanding balance of 600,000,000 RMB[160]. - The total number of shares increased from 227,454,729 to 381,246,492 shares due to various stock options and capital increases[162][164][166]. Operational Developments - The company expanded its workforce to over 2,100 professionals by the end of 2021, enhancing its service capabilities[24]. - A new 7,500 square meter breeding facility was completed and put into use by the end of 2021, supporting increased operational capacity[25]. - The company is constructing an additional 20,000 square meters of facilities to meet growing experimental demands, expected to be operational in the second half of 2022[25]. - Approximately 6,000 square meters of new experimental facilities were renovated in California to alleviate capacity constraints at the overseas subsidiary BIOMERE[26]. - The company has established a competitive compensation scheme, including stock incentives, to enhance employee motivation and retention[24]. Market Position and Strategy - The company achieved a total order amount of approximately RMB 29 billion in 2021, providing a solid foundation for future performance[33]. - The company signed orders exceeding RMB 28 billion in 2021, with domestic orders amounting to over RMB 25.5 billion, representing a year-on-year growth of approximately 65%[34]. - The overseas subsidiary BIOMERE secured orders of about RMB 2.8 billion in 2021, reflecting a year-on-year increase of approximately 75%[36]. - The company is focused on expanding its market presence through strategic partnerships and investments in biotechnology, aiming for long-term growth[109]. - The company plans to expand its market presence and is focusing on new product development and technological advancements[107]. Governance and Compliance - The financial report has been audited by KPMG Huazhen, which issued a standard unqualified opinion[2]. - The board of directors has confirmed the authenticity, accuracy, and completeness of the annual report[2]. - The company maintained independent operations and governance, ensuring no interference from controlling shareholders during the reporting period[100]. - The company has implemented measures to maintain independence in assets, personnel, and operations from controlling shareholders[101]. - The company has not faced any penalties from securities regulatory authorities in the past three years[114]. Research and Development - The company is committed to adhering to Good Laboratory Practice (GLP) standards in its research activities[7]. - The company has established a complete cell testing system in 2021, addressing the quality inspection needs for cell lines and cell banks, which is expected to become a new growth point[31]. - The company’s clinical sample testing segment has expanded to include a wide range of innovative drugs, significantly reducing method transfer time for clients[29]. - The company has developed specialized evaluation techniques for various innovative biopharmaceuticals, including gene drugs and complex antibody drugs, creating new competitive advantages[55]. - The company is investing in research and development to innovate new products, aiming to launch at least three new products in the next fiscal year[107]. Environmental Responsibility - The company emphasized the importance of environmental protection and sustainable development in its operational policies[140]. - The company has established a comprehensive environmental management system and conducts regular checks on its environmental performance[140]. - The company has committed to improving its wastewater treatment facilities to meet higher standards[143]. - The company implemented measures to reduce carbon emissions, including the use of energy-efficient LED lights and electric vehicles[144]. - The company conducted regular third-party inspections to ensure compliance with environmental discharge standards[143]. Risks and Challenges - The company faces risks from fluctuating international economic conditions and potential reductions in pharmaceutical innovation investments due to the ongoing COVID-19 pandemic[96]. - The company acknowledges the challenges posed by the COVID-19 pandemic and its potential impact on business operations, despite current control measures[98]. - The company is committed to maintaining its core competitive advantages amid increasing market competition in the non-clinical CRO industry[97]. - The company is focused on developing new technical methods to adapt to industry trends and maintain its leading position in the market[98].